ライフサイエンスコーパス: DOAC

1 DOACs demonstrated at least equal efficacy to VKA in man

2 DOACs offer simplified management of selected patients,

3 n-heparin anticoagulant with transition to a DOAC during HIT-associated thrombocytopenia).

4 Treatment with a DOAC significantly reduced the risk of major bleeding (R

5 Treatment with a DOAC significantly reduces the risks of major bleeding.

6 Rates of events for all DOACs increased among patients 75 years or older.

7 from 52.4% to 34.8% (p for trend <0.01), and DOAC use increased from 0% to 25.8% (p for trend <0.01).

8 Practice variation of OAC and DOAC use was also assessed.

9 fied patient factors associated with OAC and DOAC use.

10 nificant practice-level variation in OAC and DOAC use.

11 s in overall OAC and individual warfarin and DOAC use were analyzed.

12 ACKGROUND & AIMS: Direct oral anticoagulant (DOAC) agents increase the risk of gastrointestinal (GI)

13 Direct oral anticoagulant (DOAC) agents increase the risk of gastrointestinal (GI)

14 (VTE) compared a direct oral anticoagulant (DOAC) with vitamin K antagonists (VKAs).

15 tients receiving direct oral anticoagulants (DOAC) or warfarin for prevention of stroke and systemic

16 e development of direct oral anticoagulants (DOAC), and currently such inhibitors of thrombin and fXa

17 Direct oral anticoagulants (DOACs) are attractive options for treatment of heparin-i

18 rding the use of direct oral anticoagulants (DOACs) in the elderly, particularly bleeding risks, is u

19 availability of direct oral anticoagulants (DOACs) may improve overall OAC rates in AF patients, but

20 The direct oral anticoagulants (DOACs) represent a major advance in oral anticoagulant t

21 tly FDA-approved direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, and e

22 introduction of direct oral anticoagulants (DOACs), the search for more effective and safer antithro

23 In conclusion, DOACs and VKAs have similar efficacy in the treatment of

24 Efforts are now underway to develop DOACs that inhibit components of the intrinsic and extri

25 of objectively documented thrombosis during DOAC therapy for acute HIT.

26 ficacy in managing thrombotic risks for each DOAC was similar or superior to VKA in elderly patients.

27 lenges with regard to DOAC trials and future DOAC therapy in pediatric VTE; and discuss applicable le

28 io [MOR]: 1.52; 95% CI: 1.45 to 1.57) and in DOAC use (MOR: 3.58; 95% CI: 3.05 to 4.13).

29 ajor bleeding occurred significantly less in DOAC recipients.

30 interval [CI]: 1.05 to 1.07), but with lower DOAC use (OR: 0.97; 95% CI: 0.96 to 0.98).

31 rapy (group B; initial treatment using a non-DOAC/non-heparin anticoagulant with transition to a DOAC

32 Recurrent VTE occurred in 2.0% of DOAC recipients compared with 2.2% in VKA recipients (re

33 This study assessed the effect of DOAC availability on overall OAC rates for nonvalvular A

34 ematically searched for randomized trials of DOAC versus warfarin for prevention of stroke/SE in AF.

35 Introduction of DOACs in routine practice was associated with improved r

36 Evidence supporting efficacy and safety of DOACs for acute HIT is increasing, with the most experie

37 The efficacy and safety of DOACs were consistent in patients with pulmonary embolis

38 ew and meta-analysis of randomized trials of DOACs (dabigatran, apixaban, rivaroxaban, and edoxaban)

39 ongoing studies are assessing the utility of DOACs for the prevention of thrombosis in patients with

40 We focused on patients who received DOAC therapy for acute HIT as either primary therapy (gr

41 population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI

42 among patient aged 75 years or older taking DOACs increased with age; the risk was greatest among pe

43 t, reduction in all-cause mortality with the DOAC versus warfarin (difference -0.42%/year; 95% CI: -0

44 he DOACs, (2) describe the advantages of the DOACs over vitamin K antagonists, (3) summarize the expe

45 cle is to (1) review the pharmacology of the DOACs, (2) describe the advantages of the DOACs over vit

46 gulant therapy and improving its safety, the DOACs have the potential to reduce the global burden of

47 ticoagulants that may be even safer than the DOACs.

48 nists, (3) summarize the experience with the DOACs in established indications, (4) highlight current

49 eeded to clarify the bleeding risks of these DOACs in the elderly.

50 key questions and challenges with regard to DOAC trials and future DOAC therapy in pediatric VTE; an

51 d a literature review of HIT treatment using DOACs (rivaroxaban, apixaban, dabigatran, edoxaban).

52 We investigated which DOAC had the most favorable GI safety profile and compar

53 est that the favorable results achieved with DOACs in the randomized controlled trials can be readily